News & Videos - TONIX PHARMACEUTICALS HOLDING

Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within families and among children, whereas the 2022 Clade II mpox - still spreading - infects mostly gay men CHATHAM, NJ / ACCESS Newswire / March 20, 2025 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice. CHATHAM, NJ / ACCESS Newswire / March 12, 2025 / On any given...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice. CHATHAM, NJ / ACCESSWIRE / December 9, 2024 / Fibromyalgia,...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice. CHATHAM, NJ / ACCESSWIRE / November 14, 2024 / For millions of...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice. CHATHAM, NJ / ACCESSWIRE / October 1, 2024 / As the opioid...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice. CHATHAM, NJ / ACCESSWIRE / September 18, 2024 / The mpox...

CHATHAM, NJ / ACCESSWIRE / September 4, 2024 / (Brain Image) This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice....

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice. CHATHAM, NJ / ACCESSWIRE / August 23, 2024 / Following an...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice. CHATHAM, NJ / ACCESSWIRE / August 1, 2024 / When it comes to...

CHATHAM, NJ / ACCESSWIRE / July 24, 2024 / From anthrax to the plague, biological warfare is a real threat to U.S. forces and civilians, so much so the Pentagon budgeted about $2 billion for the country's biological defense for the coming fiscal year. It's also why the U.S. Department of Defense is seeking broad-spectrum antiviral drugs and teaming up with the biotech companies developing them. That's the case with Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a fully integrated...

CHATHAM, NJ / ACCESSWIRE / July 17, 2024 / With the completion of its final pre-NDA meeting with the FDA, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced it is filing an NDA submission in 2H 2024 and laying plans for the commercial launch of Tonmya™* for the management of fibromyalgia, assuming approval by the FDA in 2H 2025. The fibromyalgia market has not seen a new FDA-approved drug in over 15 years. And now with two drugs making their way through the FDA - Tonix's Tonmya and...

Bedtime drug being developed by Tonix relieved pain by targeting fibromyalgia's characteristic "non-restorative sleep": Potential for FDA Approval in 2025 CHATHAM, NJ / ACCESSWIRE / February 26, 2024 / People who are suffering from fibromyalgia pain are closer to a new option for treatment that targets their characteristically poor sleep quality. Tonix Pharmaceuticals (TNXP) reported positive study results for its sleep-quality targeted therapy in late December. The drug reduced widespread pain...

Non-opioid drug candidate from Tonix lowered pain and also improved sleep and fatigue Latest Phase 3 trial achieved primary endpoint (p=0.00005) Potential for FDA Approval in 2025 CHATHAM, NJ / ACCESSWIRE / February 15, 2024 / People who are suffering from fibromyalgia pain but don't want to risk addiction to an opioid are closer to a new option for treatment. Tonix Pharmaceuticals (NASDAQ:TNXP) reported positive Phase 3 study results for its non-opioid painkiller in late December. The drug...

Fibromyalgia candidate TNX-102 SL hits primary endpoint of daily pain reduction (p=0.00005) Combination of broad-spectrum relief and favorable tolerability seen as distinguishing, competitive features Company plans to file an NDA for FDA approval in 2H 2024 CHATHAM, NJ / ACCESSWIRE / February 1, 2024 / Tonix Pharmaceuticals (NASDAQ:TNXP ) appears to have a potential new weapon against fibromyalgia for the 6-12 million adults in America suffering from its debilitating effects. It has to do with...

Topline Data from a Registration-Enabling Phase 3 Clinical Trial is Due Later This Month. CHATHAM, NJ / ACCESSWIRE / December 14, 2023 / Fibromyalgia is a chronic disorder characterized by widespread pain, fatigue, sleep problems and brain fog. It is a complex condition that often overlaps with other chronic conditions such as COVID. There are an estimated 10 million U.S. adults - about 2% of the population - living with the disorder and, unfortunately, it has a high unmet need. The diagnosis of...

Tonix's Therapeutic Development Program is Aligned with National Goal for Better Solutions TONIX: Effect of TNX-102 SL on Fatigue in Proof-of-Concept Phase 2 Study Sets Stage for Developing Protocols for Registrational Phase 3 Study in Fibromyalgia-type Long COVID. CHATHAM, NJ / ACCESSWIRE / October 25, 2023 / COVID is an acute disease that comes and goes, but for a growing number of people, the sequelae to the infection - the aftereffects - can become a constellation of symptoms called long...

Malibu, CA, United States (ABN Newswire) - Join Ellis Martin for a compelling interview with Dr. Seth Lederman. He's an MD and the CEO of TONIX Pharmaceuticals Holding Corp. (NASDAQ:TNXP). Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. The company is currently developing medicines to treat conditions including long covid, fibromyalgia, lupus, organ transplant...

No Evidence of Sexual Dysfunction or Weight Gain with its Active Ingredient as a Prescription Drug Outside the U.S. Tianeptine Rescues Neuron Connectivity in Animal Models of Stress CHATHAM, NJ / ACCESSWIRE / April 27, 2023 / A new antidepressant drug candidate being developed by researchers at Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) is said to have mechanistic activity and therapeutic features that set it apart from almost all of the currently approved antidepressants in the U.S....

Thinking about buying stock in Jaguar Health, Avaya, Marathon Digital, Lucid, or Tonix Pharmaceuticals? PR Newswire NEW YORK, Jan. 11, 2023 NEW YORK , Jan. 11, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, AVYA, MARA, LCID, and TNXP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. JAGX:...

Thinking about buying stock in Geovax Labs, Aethlon Medical, Tonix Pharmaceuticals, Inflarx NV, or Redbox Entertainment? PR Newswire NEW YORK, Aug. 1, 2022 NEW YORK , Aug. 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GOVX, AEMD, TNXP, IFRX, and RDBX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. GOVX:...